Francisco J. Esteva, Chief of the Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared on LinkedIn: .
“Congratulations to Giuseppe Curigliano for the outstanding presentation of the DESTINY-Breast06 trial at the ASCO Annual Meeting.
The improvement in progression-free survival in the group of patients treated with trastuzumab deruxtecan (T-DXd, Enhertu) compared to conventional chemotherapy is statistically significant and clinically meaningful.
Practice changing study!”
Source: Francisco J. Esteva/LinkedIn